Prognostication of the high-risk WM patient

Citation:

Kastritis E, Gavriatopoulou M, Kyrtsonis M-C, Michael M, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Sioni A, et al. Prognostication of the high-risk WM patient. Clinical Lymphoma, Myeloma and Leukemia [Internet]. 2011;11(1):127 - 129.

Abstract:

Waldenström's macroglobulinemia is characterized by a protracted course in most patients and the median survival may be long. However, a subset of patients may present with more aggressive disease that is associated with short survival. In order to better characterize these "poor-risk" patients, we identified patients who died within 2 years from the initiation of front-line treatment. These patients were older and had more often features of aggressive disease, such as elevated LDH and low serum albumin than the standard-risk population. Furthermore, only a minority of poor-risk patient had a response to initial therapy. However, conventional clinical factors or even the lack on response could not adequately identify poor-risk patients, indicating the need for novel molecular or other markers that would be able to effectively recognize patients at greatest need for aggressive therapies. © 2011 Elsevier Inc. All rights reserved.

Notes:

Export Date: 21 February 2017

Website